In This Article:
-
Total Net Product Revenue: $612 million, representing 70% growth over the same quarter last year.
-
ELEVIDYS Revenue: $375 million, a 180% increase year-over-year.
-
PMO Franchise Revenue: $237 million, a 5% increase over the prior year.
-
Total Revenues: $745 million, an 80% increase year-over-year.
-
Cash Position: $647 million in cash, cash equivalents, investments, and restricted cash.
-
Operating Loss (GAAP): $300 million, including $584 million R&D expense related to Arrowhead collaboration.
-
Operating Profit (Non-GAAP): $334 million, excluding Arrowhead transaction.
-
Revised Revenue Guidance for 2025: $2.3 billion to $2.6 billion.
-
R&D Expenses (GAAP): $773 million, a year-over-year increase of $573 million.
-
SG&A Expenses (GAAP): $134 million, up 5% year-over-year.
-
Net Loss (GAAP): $448 million or $4.60 per share.
-
Net Loss (Non-GAAP): $332 million or $3.42 per share.
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Sarepta Therapeutics Inc (NASDAQ:SRPT) achieved $612 million in total net product revenue for Q1 2025, representing a 70% growth over the same quarter last year.
-
ELEVIDYS sales reached $375 million in Q1, marking a 180% increase over the same quarter last year.
-
The company maintains a strong cash position with $647 million in cash, cash equivalents, and investments, plus an additional $600 million available through a revolving credit facility.
-
Sarepta Therapeutics Inc (NASDAQ:SRPT) has four approved therapies generating significant revenue and growth potential.
-
The company is actively working to expand its site capacity and improve administrative processes to enhance patient access to ELEVIDYS.
Negative Points
-
Sarepta Therapeutics Inc (NASDAQ:SRPT) revised its net product revenue guidance for 2025 to $2.3 billion to $2.6 billion, down from previous expectations.
-
A tragic safety event involving a patient death due to acute liver failure has impacted the company's reputation and caused delays in patient infusions.
-
The administrative process for gene therapy infusions is complex, leading to delays and impacting revenue timing.
-
There is an imbalance in site capacity, with top sites being fully booked, which limits immediate patient access.
-
The company faces challenges in educating the broader physician and patient community about the safety and efficacy of ELEVIDYS, impacting uptake.
Q & A Highlights
Q: Doug, regarding the three factors you mentionedcapacity issues, administrative processes, and patient concernswhat has been the biggest driver of the revised guidance? Have any of these factors worsened in Q2? A: The cycle times are the most impactful on forward guidance. We haven't seen a worsening, and we believe we're at a steady state. The first quarter had unique challenges like a severe flu season and typical insurance changes, which may have extended cycle times. The safety event also caused delays, but we're seeing positive signs as we educate the broader community.